Do weight-loss drugs like Ozempic also protect the heart?
Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether drugs like Ozempic and Tirzepatide, used for weight loss, also help prevent heart problems in people who are overweight but don’t have diabetes.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 539 / 100
Evidence Score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether drugs like Ozempic and Tirzepatide, used for weight loss, also help prevent heart problems in people who are overweight but don’t have diabetes.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 539 / 100
Evidence Score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Publication
Authors
Yin Y, Zhang M, Cao Q, Lin L, Lu J, Bi Y, Chen Y
Related Content
Claims (6)
In adults who are overweight or obese but do not have diabetes, medications that activate GLP-1 receptors lower the likelihood of heart attacks, strokes, and other serious heart-related events compared to a placebo.
In adults who are overweight or obese but do not have diabetes, tirzepatide lowers both body mass index and blood sugar levels compared to other similar medications.
In nondiabetic adults with overweight or obesity, the drug Retatrutide lowers levels of LDL cholesterol and triglycerides in the blood by specific amounts, and based on current data, it shows greater lipid-lowering effects than other GLP-1 receptor agonist drugs.
In nondiabetic adults with overweight or obesity, medications that activate GLP-1 receptors are associated with a 19% lower risk of death from any cause, but this reduction is mainly due to one large study and does not hold up when that study is removed from the analysis.
In adults with overweight or obesity who do not have diabetes, the medication orforglipron lowers systolic blood pressure by an average of 7.1 mmHg more than other similar medications in the same class.